斯奇康佐治疗支气管哮喘的临床观察

Clinic observation of Siqikang assistant treating bronchial ashma

目的:探讨斯奇康(卡介菌多糖核酸)对支气管哮喘的辅助治疗作用及其机制.方法:将90例轻度持续和中度持续的支气管哮喘患儿随机分为治疗组和对照组,治疗组除常规吸入哮喘药物外接受斯奇康肌注,随访观察、调整治疗3个月.治疗组于治疗前后查血清CD3、CD4、CD8水平.结果:治疗组患者哮喘的有效控制较容易,1～3个月内升级治疗的机率小.3个月时治疗组血清CD3不变,CD4及CD4/CD8比值明显降低.结论:斯奇康可以作为哮喘的一种辅助治疗方法,它通过抑制哮喘患儿体内过度活化的CD4淋巴细胞,抑制Th2分泌IL-4,从而调整Th1/Th2的动态平衡,而达到治疗目的.

Objective： To investigate therapeutic effect and mechanism of Siqikang （polysaccharide nucleic acid fraction of bacillus＇calmette guerin： BCG-PNS） for bronchial asthma. Methods： 90 cases of mild to middle degree persistent bronchial asthma children were randomly divided into two groups. 45 cases in the control group were treated with ashma drugs only, 45 cases in treatment group were treated with BCG-PSN plus asthma drugs. All cases were followed and observed for three monthes. CD3, CD4, CD8 were examined before and after treatment for treatment group. Results. Bronchial asthma of treatment group were effectively controlled more easily than that of control groups. The chance of upgrade treatment was lower in treatment group than that in control group. Serum CD3 was unchanged, CD4 and CD4/CD8 were obviously reduced in 3 months for the treatment group. Conclusion： BCG-PSN could be used to assist in treating asthma, it may be mechanism of BCG-PSN treating for asthma that BCG-PSN inhibits over activated CD4 T-lymphocyte, Th2 cell secreting IL-4 and ameliorate the balance of Th1/Th2.